← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity

SEPN logoSepterna, Inc.(SEPN)Earnings, Financials & Key Ratios

SEPN•NASDAQ
$23.98
$1.07B mkt cap·Price updated May 7, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryMetabolic and Obesity Therapies
AboutSepterna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves' disease and thyroid eye disease. It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes. Septerna, Inc. was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. The company was incorporated in 2019 and is headquartered in South San Francisco, California.Show more
  • Revenue$46M+4174.5%
  • EBITDA-$68M+14.0%
  • Net Income-$49M+31.9%
  • EPS (Diluted)-1.10+84.8%
  • EBITDA Margin-148.63%+98.0%
  • Operating Margin-148.63%+98.0%
  • Net Margin-106.37%+98.4%
  • ROE-12.19%+67.6%
  • ROIC-20.82%+84.0%
  • Debt/Equity0.06+2.0%
Technical→

SEPN Key Insights

Septerna, Inc. (SEPN) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Company is almost debt free
  • ✓FCF machine: 238.7% free cash flow margin

✗Weaknesses

  • ✗Shares diluted 100.0% in last year
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

SEPN Price & Volume

Septerna, Inc. (SEPN) stock price & volume — 10-year historical chart

Loading chart...

SEPN Growth Metrics

Septerna, Inc. (SEPN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years-
3 Years-
TTM-

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-

Return on Capital

10 Years-32.9%
5 Years-32.9%
3 Years-13.37%
Last Year-14.33%

SEPN Recent Earnings

Septerna, Inc. (SEPN) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 1/8 qtrs (17%)●Beat Revenue 2/8 qtrs (50%)
Q2 2026Latest
Mar 9, 2026
EPS
$0.24
Est $0.23
-4.3%
Revenue
$24M
Est $18M
+32.5%
Q4 2025
Nov 10, 2025
EPS
$0.09
Est $0.19
-147.4%
Revenue
$21M
Est $17M
+24.5%
Q3 2025
Aug 11, 2025
EPS
$0.56
Est $0.05
-1020.0%
Revenue
$119,000
Est $5M
-97.6%
Q2 2025
May 15, 2025
EPS
$0.49
Est $0.38
-28.9%
Revenue
$219,000
Est $30M
-99.3%
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMar 9, 2026
$0.24vs $0.23-4.3%
$24Mvs $18M+32.5%
Q4 2025Nov 10, 2025
$0.09vs $0.19-147.4%
$21Mvs $17M+24.5%
Q3 2025Aug 11, 2025
$0.56vs $0.05-1020.0%
$119,000vs $5M-97.6%
Q2 2025May 15, 2025
$0.49vs $0.38-28.9%
$219,000vs $30M-99.3%
Based on last 8 quarters of dataView full earnings history →

SEPN Peer Comparison

Septerna, Inc. (SEPN) competitors in Metabolic and Obesity Therapies — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
KYMR logoKYMRKymera Therapeutics, Inc.Direct Competitor6.91B84.63-22.94-16.72%-6.12%-25.02%0.05
RXRX logoRXRXRecursion Pharmaceuticals, Inc.Direct Competitor1.46B3.27-2.2726.92%-8.44%-54.32%0.07
VKTX logoVKTXViking Therapeutics, Inc.Direct Competitor3.66B31.58-9.90-71.31%0.00
GPCR logoGPCRStructure Therapeutics Inc.Direct Competitor2.25B39.15-16.31-15.12%0.00
ACLX logoACLXArcellx, Inc.Direct Competitor6.73B115.07-28.27-79.35%-10.27%-55.42%0.24
TPVG logoTPVGTriplePoint Venture Growth BDC Corp.Direct Competitor242.54M5.994.9136.55%-3.39%1.33
ARWR logoARWRArrowhead Pharmaceuticals, Inc.Product Competitor10.92B77.95-6389.34232.58%-48.38%-55.47%0.73
PRAX logoPRAXPraxis Precision Medicines, Inc.Product Competitor9.63B333.28-24.72-100%-43.02%0.00

Compare SEPN vs Peers

Septerna, Inc. (SEPN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs KYMR

Most directly comparable listed peer for SEPN.

Scale Benchmark

vs LLY

Larger-name benchmark to compare SEPN against a more recognizable public peer.

Peer Set

Compare Top 5

vs KYMR, RXRX, VKTX, GPCR

SEPN Income Statement

Septerna, Inc. (SEPN) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
Line itemDec'22Dec'23Dec'24Dec'25
Sales/Revenue0151K1.07M45.95M
Revenue Growth %--611.92%4174.51%
Cost of Goods Sold0000
COGS % of Revenue----
Gross Profit
0▲ 0%
151K▲ 0%
1.07M▲ 611.9%
0▼ 100.0%
Gross Margin %-100%100%-
Gross Profit Growth %--611.92%-100%
Operating Expenses27.97M-1.92M81.9M126.75M
OpEx % of Revenue--1274.17%7618.42%275.83%
Selling, General & Admin5.92M9.72M16.56M29.16M
SG&A % of Revenue-6438.41%1540.56%63.47%
Research & Development22.04M35.98M65.34M97.58M
R&D % of Revenue-23827.15%6077.86%212.37%
Other Operating Expenses0-47.63M00
Operating Income
-27.97M▲ 0%
2.08M▲ 107.4%
-80.82M▼ 3995.1%
-68.3M▲ 15.5%
Operating Margin %-1374.17%-7518.42%-148.63%
Operating Income Growth %-107.42%-3995.08%15.5%
EBITDA-27.39M2.92M-79.42M-68.3M
EBITDA Margin %-1935.76%-7388.09%-148.63%
EBITDA Growth %-110.67%-2817.14%14.01%
D&A (Non-Cash Add-back)577K848K1.4M0
EBIT-27.97M-45.55M-80.82M0
Net Interest Income291K2.79M8.62M0
Interest Income291K2.79M8.62M19.53M
Interest Expense0000
Other Income/Expense291K2.8M8.53M19.43M
Pretax Income
-27.68M▲ 0%
4.87M▲ 117.6%
-72.3M▼ 1584.2%
-48.87M▲ 32.4%
Pretax Margin %-3225.83%-6725.21%-106.35%
Income Tax0691K-498K12K
Effective Tax Rate %0%14.19%0.69%-0.02%
Net Income
-27.68M▲ 0%
4.18M▲ 115.1%
-71.8M▼ 1817.7%
-48.88M▲ 31.9%
Net Margin %-2768.21%-6678.88%-106.37%
Net Income Growth %-115.1%-1817.66%31.92%
Net Income (Continuing)-27.68M4.18M-71.8M-48.88M
Discontinued Operations0000
Minority Interest0000
EPS (Diluted)
-1.42▲ 0%
0.03▲ 102.0%
-7.26▼ 25048.5%
-1.10▲ 84.8%
EPS Growth %-102.05%-25048.45%84.85%
EPS (Basic)-1.420.03-7.26-1.10
Diluted Shares Outstanding19.5M19.5M9.89M44.26M
Basic Shares Outstanding19.5M19.5M9.89M44.26M
Dividend Payout Ratio----

SEPN Balance Sheet

Septerna, Inc. (SEPN) balance sheet — assets, liabilities & shareholders' equity

Line itemDec'22Dec'23Dec'24Dec'25
Total Current Assets31.89M112.68M356.82M410.96M
Cash & Short-Term Investments30.61M88.48M350.92M391.09M
Cash Only30.61M88.48M238.2M120.72M
Short-Term Investments00112.73M270.37M
Accounts Receivable022.78M1.12M10.36M
Days Sales Outstanding-55.05K381.6482.26
Inventory0000
Days Inventory Outstanding----
Other Current Assets204K92K200K9.52M
Total Non-Current Assets4.23M18.19M99.73M185.22M
Property, Plant & Equipment3.1M17.19M28.69M25.93M
Fixed Asset Turnover-0.01x0.04x1.77x
Goodwill0000
Intangible Assets0000
Long-Term Investments0069.87M0
Other Non-Current Assets1.12M1M1.17M159.29M
Total Assets
36.12M▲ 0%
130.87M▲ 262.3%
456.55M▲ 248.9%
596.19M▲ 30.6%
Asset Turnover-0.00x0.00x0.08x
Asset Growth %-262.32%248.87%30.58%
Total Current Liabilities5.54M6.91M12.85M86.93M
Accounts Payable3.07M2.64M3.2M10.28M
Days Payables Outstanding----
Short-Term Debt0002.21M
Deferred Revenue (Current)00062.27M
Other Current Liabilities1.76M3.04M4.21M22.45M
Current Ratio5.75x16.30x27.77x4.73x
Quick Ratio5.75x16.30x27.77x4.73x
Cash Conversion Cycle----
Total Non-Current Liabilities74.78M162.33M23.66M127.33M
Long-Term Debt00021.41M
Capital Lease Obligations012.57M23.63M0
Deferred Tax Liabilities0000
Other Non-Current Liabilities74.78M149.76M33K105.92M
Total Liabilities80.32M169.24M36.51M214.26M
Total Debt710K12.57M25.48M23.63M
Net Debt-29.9M-75.92M-212.72M-97.1M
Debt / Equity--0.06x0.06x
Debt / EBITDA-4.30x--
Net Debt / EBITDA--25.97x--
Interest Coverage----
Total Equity
-44.2M▲ 0%
-38.37M▲ 13.2%
420.05M▲ 1194.6%
381.93M▼ 9.1%
Equity Growth %-13.18%1194.61%-9.08%
Book Value per Share-2.27-1.9742.478.63
Total Shareholders' Equity-44.2M-38.37M420.05M381.93M
Common Stock3K3K44K45K
Retained Earnings-50.76M-46.58M-118.37M-167.25M
Treasury Stock0000
Accumulated OCI0056K617K
Minority Interest0000

SEPN Cash Flow Statement

Septerna, Inc. (SEPN) cash flow — operating, investing & free cash flow history

Line itemDec'22Dec'23Dec'24Dec'25
Cash from Operations-23.3M-38.72M-67.47M110.19M
Operating CF Margin %--25644.37%-6276.28%239.8%
Operating CF Growth %--66.17%-74.24%263.32%
Net Income-27.68M4.18M-71.8M-48.88M
Depreciation & Amortization577K848K1.4M1.6M
Stock-Based Compensation1.52M1.62M3.15M8.48M
Deferred Taxes0491K-491K0
Other Non-Cash Items530K-46.79M18K148.99M
Working Capital Changes1.75M926K248K0
Change in Receivables0-151K-20K-10.19M
Change in Inventory0000
Change in Payables1.73M-653K723K6.6M
Cash from Investing-1.29M22.12M-160.6M-229.35M
Capital Expenditures-1.29M-2.88M-2.1M-518K
CapEx % of Revenue-1905.96%195.63%1.13%
Acquisitions0000
Investments----
Other Investing025M22.63M12.5M
Cash from Financing30.05M74.52M377.78M1.69M
Debt Issued (Net)0000
Equity Issued (Net)1000K1000K1000K0
Dividends Paid0000
Share Repurchases0-1K-1K-1K
Other Financing82K052K1.69M
Net Change in Cash
5.46M▲ 0%
57.92M▲ 961.0%
149.71M▲ 158.5%
-117.47M▼ 178.5%
Free Cash Flow
-24.59M▲ 0%
-41.6M▼ 69.2%
-69.57M▼ 67.2%
109.67M▲ 257.6%
FCF Margin %--27550.33%-6471.91%238.67%
FCF Growth %--69.16%-67.24%257.63%
FCF per Share-1.26-2.13-7.032.48
FCF Conversion (FCF/Net Income)0.84x-9.26x0.94x-2.25x
Interest Paid0000
Taxes Paid075K232K0

SEPN Key Ratios

Septerna, Inc. (SEPN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric2022202320242025
Return on Equity (ROE)---37.62%-12.19%
Return on Invested Capital (ROIC)---130.31%-20.82%
Gross Margin-100%100%-
Net Margin-2768.21%-6678.88%-106.37%
Debt / Equity--0.06x0.06x
FCF Conversion0.84x-9.26x0.94x-2.25x
Revenue Growth--611.92%4174.51%

SEPN SEC Filings & Documents

Septerna, Inc. (SEPN) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Apr 13, 2026·SEC

Material company update

Mar 9, 2026·SEC

Material company update

Mar 2, 2026·SEC

10-K Annual Reports

2
FY 2026

Mar 9, 2026·SEC

FY 2025

Mar 27, 2025·SEC

10-Q Quarterly Reports

4
FY 2025

Nov 10, 2025·SEC

FY 2025

Aug 11, 2025·SEC

FY 2025

May 15, 2025·SEC

SEPN Frequently Asked Questions

Septerna, Inc. (SEPN) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Septerna, Inc. (SEPN) reported $46.0M in revenue for fiscal year 2025.

Septerna, Inc. (SEPN) grew revenue by 4174.5% over the past year. This is strong growth.

Septerna, Inc. (SEPN) reported a net loss of $48.9M for fiscal year 2025.

Dividend & Returns

Septerna, Inc. (SEPN) has a return on equity (ROE) of -12.2%. Negative ROE indicates the company is unprofitable.

Septerna, Inc. (SEPN) generated $109.7M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More SEPN

Septerna, Inc. (SEPN) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.